View Older Stories View More Recent Stories

Sep 3, 2019 09:00AM Incyte Launches #MyMPNChallenge to Inspire the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month
Sep 3, 2019 08:14AM Incyte (INCY) Announces Data from its Oncology Portfolio to be Featured at ESMO
Sep 3, 2019 08:14AM Data from Incyte’s Oncology Portfolio to be Featured at the 2019 ESMO Congress
Aug 23, 2019 02:58PM Eli Lilly & Co. (LLY), Incyte (INCY) Baricitinib Met Primary Endpoint in BREEZE-AD7 Trial
Aug 23, 2019 02:55PM Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
Aug 22, 2019 08:00AM Incyte to Present at Upcoming Investor Conferences
Jul 30, 2019 07:00AM Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Jul 11, 2019 08:00AM Incyte to Report Second Quarter Financial Results
Jul 2, 2019 07:32AM Incyte (INCY), Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
Jul 2, 2019 07:30AM Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
Jul 2, 2019 07:30AM Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
Jul 2, 2019 07:30AM Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
Jun 17, 2019 05:43AM Incyte (INCY) Reports Positive Results from Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
Jun 15, 2019 03:25AM Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
Jun 4, 2019 07:31AM Incyte (INCY) Reports First Patient Treated in Phase 3 Clinical Trial of Pemigatinib as First-Line Therapy for Cholangiocarcinoma
Jun 4, 2019 07:30AM Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Pemigatinib as a First-Line Therapy for Cholangiocarcinoma
Jun 3, 2019 01:45AM New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results in Patients with Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation Treated with Capmatinib
May 24, 2019 01:45PM Incyte (INCY) Confirms FDA Approval of Jakafi for GVHD
May 24, 2019 01:43PM FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease
May 23, 2019 08:00AM Incyte to Present at Upcoming Investor Conference
May 20, 2019 07:30AM Data from Incyte’s Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology
May 16, 2019 12:01PM Incyte (INCY) Announces Abstracts Accepted for Presentation at ASCO and EHA
May 16, 2019 12:00PM Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA
May 2, 2019 08:00AM Incyte to Present at Upcoming Investor Conferences
Apr 30, 2019 07:00AM Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Apr 11, 2019 08:00AM Incyte to Report First Quarter Financial Results
Feb 28, 2019 10:30AM Incyte Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2019
Feb 28, 2019 08:00AM Data from Incyte’s Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019
Feb 19, 2019 08:00AM Incyte to Present at Upcoming Investor Conferences
Feb 14, 2019 07:00AM Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs
Feb 7, 2019 07:14AM Incyte (INCY) Says FDA Extended Review Period for Ruxolitinib in Acute Graft-Versus-Host Disease
Feb 7, 2019 07:00AM Incyte Announces U.S. FDA Has Extended the Review Period for Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease
Feb 4, 2019 06:46AM Eli Lilly & Co. (LLY), Incyte Corporation (INCY) Report Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Feb 4, 2019 06:45AM Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Jan 24, 2019 08:00AM Incyte to Report Fourth Quarter and Year-end Financial Results
Jan 22, 2019 07:30AM Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease
Jan 3, 2019 07:03AM Incyte (INCY) Names Christiana Stamoulis CFO
Jan 3, 2019 07:00AM Incyte Appoints Christiana Stamoulis as Chief Financial Officer
Dec 20, 2018 04:31PM Incyte (INCY) Reports First Patient Treated in Phase 3 Clinical Trial Program for Ruxolitinib Cream in Atopic Dermatitis
Dec 20, 2018 04:30PM Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program for Ruxolitinib Cream in Atopic Dermatitis
Dec 16, 2018 05:40PM Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China
Dec 16, 2018 05:35PM Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China
Dec 13, 2018 08:00AM Incyte to Present at Upcoming Investor Conferences
Dec 13, 2018 06:48AM Lilly (LLY) and Incyte (INCY) Announce FDA Granted Fast Track Designation to Baricitinib Development Program for Treatment of SLE
Dec 13, 2018 06:45AM FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Dec 3, 2018 10:02AM Incyte (INCY) Announces Results of REACH1 Study of Ruxolitinib for Treatment of Acute GVHD Demonstrate Rapid and Durable Patient Benefit
Dec 3, 2018 10:00AM Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit
Nov 27, 2018 07:30AM Incyte (INCY) Appoints Dr. Dashyant Dhanak as Chief Scientific Officer
Nov 27, 2018 07:30AM Incyte Appoints Dr. Dashyant Dhanak as Chief Scientific Officer
Nov 7, 2018 08:00AM Incyte to Present at Upcoming Investor Conference
View More Recent Stories View Older Stories